Cost-effectiveness of a new rotavirus vaccination program in Pakistan: A decision tree model

被引:16
作者
Patel, Hiten D. [1 ,2 ]
Roberts, Eric T. [3 ]
Constenla, Dagna O. [4 ]
机构
[1] Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA
关键词
Rotavirus; Gastroenteritis; Cost-effectiveness; Vaccination; Pakistan; GLOBAL BURDEN; DISEASE; CHILDREN; GASTROENTERITIS; SURVEILLANCE; EFFICACY; HEALTH; IMPACT; IMMUNIZATION; STRATEGIES;
D O I
10.1016/j.vaccine.2013.10.022
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Rotavirus gastroenteritis places a significant health and economic burden on Pakistan. To determine the public health impact of a national rotavirus vaccination program, we performed a cost-effectiveness study from the perspective of the health care system. Methods: A decision tree model was developed to assess the cost-effectiveness of a national vaccination program in Pakistan. Disease and cost burden with the program were compared to the current state. Disease parameters, vaccine-related costs, and medical treatment costs were based on published epidemiological and economic data, which were specific to Pakistan when possible. An annual birth cohort of children was followed for 5 years to model the public health impact of vaccination on health-related events and costs. The cost-effectiveness was assessed and quantified in cost (2012 US$) per disability-adjusted life-year (DALY) averted and cost per death averted. Sensitivity analyses were performed to assess the robustness of the incremental cost-effectiveness ratios (ICERs). Results: The base case results showed vaccination prevented 1.2 million cases of rotavirus gastroenteritis, 93,000 outpatient visits, 43,000 hospitalizations, and 6700 deaths by 5 years of age for an annual birth cohort scaled from 6% current coverage to DPT3 levels (85%). The medical cost savings would be US$1.4 million from hospitalizations and US$200,000 from outpatient visit costs. The vaccination program would cost US$35 million at a vaccine price of US$5.00. The ICER was US$149.50 per DALY averted or US$4972 per death averted. Sensitivity analyses showed changes in case-fatality ratio, vaccine efficacy, and vaccine cost exerted the greatest influence on the ICER. Conclusions: Across a range of sensitivity analyses, a national rotavirus vaccination program was predicted to decrease health and economic burden due to rotavirus gastroenteritis in Pakistan by similar to 40%. Vaccination was highly cost-effective in this context. As discussions of implementing the intervention intensify, future studies should address affordability, efficiency, and equity of vaccination introduction. 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6072 / 6078
页数:7
相关论文
共 50 条
  • [31] Cost-effectiveness of rotavirus vaccination in Kenya and Uganda
    Sigei, Charles
    Odaga, John
    Mvundura, Mercy
    Madrid, Yvette
    Clark, Andrew David
    VACCINE, 2015, 33 : A109 - A118
  • [32] Impact and cost-effectiveness of rotavirus vaccination in Bangladesh
    Pecenka, Clint
    Parashar, Umesh
    Tate, Jacqueline E.
    Khan, Jahangir A. M.
    Groman, Devin
    Chacko, Stephen
    Shamsuzzaman, Md
    Clark, Andrew
    Atherly, Deborah
    VACCINE, 2017, 35 (32) : 3982 - 3987
  • [33] Cost-Effectiveness of Rotavirus Vaccination: Exploring Caregiver(s) and "No Medical Care" Disease Impact in Belgium
    Bilcke, Joke
    Van Damme, Pierre
    Beutels, Philippe
    MEDICAL DECISION MAKING, 2009, 29 (01) : 33 - 50
  • [34] Cost-effectiveness estimates of vaccination against rotavirus in Piedmont, Italy
    Gualano, Maria R.
    Thomas, Robin
    Gili, Renata
    Scaioli, Giacomo
    Voglino, Gianluca
    Zotti, Carla
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2018, 11 (06) : 867 - 872
  • [35] Cost-effectiveness of rotavirus vaccination in Bolivia from the state perspective
    Smith, Emily R.
    Rowlinson, Emily E.
    Iniguez, Volga
    Etienne, Kizee A.
    Rivera, Rosario
    Mamani, Nataniel
    Rheingans, Rick
    Patzi, Maritza
    Halkyer, Percy
    Leon, Juan S.
    VACCINE, 2011, 29 (38) : 6704 - 6711
  • [36] Projected health impact and cost-effectiveness of rotavirus vaccination among children <5 years of age in China
    Liu, Na
    Yen, Catherine
    Fang, Zhao-yin
    Tate, Jacqueline E.
    Jiang, Baoming
    Parashar, Umesh D.
    Zeng, Guang
    Duan, Zhao-jun
    VACCINE, 2012, 30 (48) : 6940 - 6945
  • [37] An update to "The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe"
    Jit, Mark
    Mangen, Marie-Josee J.
    Melliez, Hugues
    Yazdanpanah, Yazdan
    Bilcke, Joke
    Salo, Heini
    Edmunds, W. John
    Beutels, Philippe
    VACCINE, 2010, 28 (47) : 7457 - 7459
  • [38] Public finance of rotavirus vaccination in India and Ethiopia: An extended cost-effectiveness analysis
    Verguet, Stephane
    Murphy, Shane
    Anderson, Benjamin
    Johansson, Kjell Arne
    Glass, Roger
    Rheingans, Richard
    VACCINE, 2013, 31 (42) : 4902 - 4910
  • [39] Re-evaluation of the cost-effectiveness and effects of childhood rotavirus vaccination in Norway
    Edwards, Christina Hansen
    de Blasio, Birgitte Freiesleben
    Salamanca, Beatriz Valcarcel
    Flem, Elmira
    PLOS ONE, 2017, 12 (08):
  • [40] The cost-effectiveness of rotavirus vaccination in Australia
    Newall, Anthony T.
    Beutels, Philippe
    Macartney, Kristine
    Wood, James
    MacIntyre, C. Raina
    VACCINE, 2007, 25 (52) : 8851 - 8860